Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 1726 • ACR Convergence 2023
Therapeutic Effect of ICAM-1 Mimic on Experimental Axial Spondyloarthritis
Melissa Lim¹, Shaghayegh Foroozan², Zoya Qaiyum³, Michael Tang¹, Enoch Yau⁴ and Robert Inman¹, ¹University Health Network, Toronto, ON, Canada, ²University Health Network/University of Toronto, Toronto, ON, Canada, ³Krembil Research Institute, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: Axial Spondyloarthritis (AxSpA) is a chronic inflammatory arthritis primarily affecting the axial skeleton and commonly coexists with gut and skin inflammation. Currently, patients with…
Abstract Number: 2442 • ACR Convergence 2023
Neutrophils Induce Contact-Dependent Expansion of Arthritogenic Th17 Cells and Are Necessary for Disease in Experimental Ankylosing Spondylitis
Hillary Struthers¹, Emily Vance¹, Kofi Asare-Konadu¹, Holly Rosenzweig² and Ruth Napier¹, ¹Oregon Health & Science University, Portland, OR, ²VA Portland Healthcare System, Portland, OR
Background/Purpose: Ankylosing spondylitis (AS) patients have irregular neutrophil responses, as indicated clinically by neutrophilia and increased neutrophil to lymphocyte ratios that positively associate with disease…
Abstract Number: 0333 • ACR Convergence 2023
Ankylosing Spondylitis Patient Perspective on Living with Flares and Impact on Quality of Life
Heather Lapidus Glassner and Elizabeth Luce, MyHealthTeam, San Francisco, CA
Background/Purpose: Ankylosing spondylitis (AS) leads to symptoms of pain, stiffness, swelling, and fatigue. Patients often report periods of increased symptoms (flares) followed by remission.The purpose…
Abstract Number: 0539 • ACR Convergence 2023
Impact of Extreme Baseline BASDAI and/or Maastricht AS Enthesitis Score on Treatment Response to Upadacitinib in Patients with Axial Spondyloarthritis
Maxime Dougados¹, David Bulbin², Heather Jones³, Tianming Gao⁴, Anna Shmagel⁵, Thomas Poznanski⁶, Abhijeet Danve⁷ and Karl Gaffney⁸, ¹Université de Paris, Paris, France, ²Geisinger Health System, Danville, PA, ³AbbVie, Inc., Mettawa, IL, ⁴AbbVie, Inc., North Chicago, IL, ⁵AbbVie, Inc., Long Grove, IL, ⁶AbbVie, Inc., Plainfield, IL, ⁷Yale University, New Haven, CT, ⁸Norfolk and Norwich University Hospital NHS Trust, Norfolk, United Kingdom
Background/Purpose: Axial SpA (axSpA) and FM manifest with overlapping clinical features such as pain, fatigue, and stiffness, yet their treatment is distinctly different. FM is…
Abstract Number: 1394 • ACR Convergence 2023
Comorbidities, Not Long-Term Use of Nonsteroidal Anti-Inflammatory Drugs, May Be Associated with Chronic Kidney Disease in Patients with Ankylosing Spondylitis: A Nationwide Population-Based Study
Bon San Koo¹, Subin Hwang¹, Ye-Jee Kim², Soo Min Ahn² and Wook Jang Seo³, ¹Inje University Seoul Paik Hospital, Seoul, South Korea, ²Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, ³Department of Rheumatology, Veteran Health Service Medical Center, Seoul, South Korea
Background/Purpose: Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed as first-line treatment for symptom relief and inflammation reduction in patients with ankylosing spondylitis (AS). However, long-term…
Abstract Number: 1783 • ACR Convergence 2023
Integrative Functional Genomics Points to Natural Killer Cells as Key Drivers in the Pathogenesis of Ankylosing Spondylitis
Marcos Chiñas¹, Daniela Fernandez-Salinas¹, Vitor Aguiar¹, Victor Caballero-Nieto², Micah Lefton³, Joerg Ermann⁴ and Maria Gutierrez-Arcelus¹, ¹Boston Children's Hospital, Boston, MA, ²Boston Children's Hospital, Montpellier, France, ³Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Multiple lines of evidence indicate that ankylosing spondylitis (AS) is a lymphocyte-driven disease. However, which lymphocyte populations are critical in AS pathogenesis is not…
Abstract Number: 2545 • ACR Convergence 2023
Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Axial Spondyloarthritis: Results from a Randomized, Double-Blind, Phase 3 Study
Atul Deodhar¹, Jerzy Supronik², Alan Kivitz³, Guillermo Valenzuela⁴, Karen Kapur⁵, Susanne Rohrer⁶, Eva Dokoupilova⁷, Hanno Richards⁶ and Karel Pavelka⁸, ¹Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR, ²OsteoMedic sc A Racewicz J Supronik, Bialystok, Poland, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Integral Rheumatology & Immunology Specialists, Plantation, FL, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology; MEDICAL PLUS sro, Brno, Czech Republic, ⁸Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic
Background/Purpose: While subcutaneous secukinumab (SEC) is approved for the treatment of axial spondyloarthritis (axSpA), some patients may benefit more from intravenous (IV) administration. This study…
Abstract Number: 0500 • ACR Convergence 2023
Analysis of the Probability of Retention of Golimumab as a Two-phase Exponential Decay Curve in Rheumatoid Arthritis or Spondyloarthropathies to Identify Patients with Higher Probability of Long-term Retention
Jose Federico Diaz-Gonzalez¹, Luis Cea-Calvo², Enrique González-Dávila³, Marta Sánchez-Jareño², Manuel Enrique Pombo Suarez⁴, Fernando Alonso⁵ and Isabel Castrejon⁶, ¹Hospital Universitario de Canarias, La Laguna, Spain, ²Medical Affairs, MSD Spain, Madrid, Spain, ³Department of Mathematics, Statistics and Operation Reseach La Laguna University, La Laguna, Spain, ⁴Hospital Clínico Universitario, Santiago de Compostela, Spain, ⁵Spanish Society of Rheumatology, Madrid, Spain, ⁶Hospital Universitario Gregorio Marañón, Madrid, Spain
Background/Purpose: Selecting patients with the highest probability of long-term retention of biological treatments is important from a clinical and cost-effectiveness point of view. In this…
Abstract Number: 0540 • ACR Convergence 2023
The Impact of Baseline BMI and Physical Activity on Upadacitinib Treatment Response: A Post Hoc Analysis of Patients with Ankylosing Spondylitis from the SELECT-AXIS 2 Study
Angela Crowley¹, Lori Siegel¹, Pendleton Wickersham², Heather Jones³, Dan Webster⁴, Anna Shmagel⁵, Ana Biljan⁶, Uta Kiltz⁷ and Philip Helliwell⁸, ¹Illinois Bone and Joint Institute, Gurnee and Hinsdale, IL, ²Methodist Hospital, Baptist Medical Center and CHRISTUS Santa Rosa Hospital - Westover Hills, San Antonio, TX, ³AbbVie, Inc., Mettawa, IL, ⁴AbbVie, Inc., Libertyville, IL, ⁵AbbVie, Inc., Long Grove, IL, ⁶AbbVie, Inc., Buffalo Grove, IL, ⁷Rheumazentrum Ruhrgebiet, Herne, Germany, ⁸University of Leeds, Leeds, United Kingdom
Background/Purpose: In patients (pts) with AS, higher BMI has been linked to higher disease activity1. However, given that BMI can be a poor indicator of…
Abstract Number: 1395 • ACR Convergence 2023
Aerobic Capacity and Its Relation to Disease Characteristics and Lifestyle Habits in Patients with Axial Spondyloarthritis
Elisabet Lindqvist¹, Johan Karlsson Wallman¹, Jonas Sagard², Tor Olofsson¹ and Elisabeth Mogard¹, ¹Lund University and Skåne University Hospital, Lund, Sweden, ²Skåne University Hospital, Lund, Sweden
Background/Purpose: Physical activity is part of the treatment of axial spondyloarthritis (axSpA), but despite this almost half of the patients do not meet the required…
Abstract Number: 1786 • ACR Convergence 2023
Newly Identified Gut Commensal Clostridium Fessum AM100 for Treating Ankylosing Spondylitis
Lu Bai¹, Chengkai Zhu¹, Yihong Xu², Kunhai Tang¹, Dachun Zhuo¹, Qing Zhang¹, Chengchun Geng¹, Weidong Xu², Hao Wu¹, Xingdong Chen¹ and Jiucun Wang¹, ¹Fudan University, Shanghai, China, ²Changhai Hospital, Shanghai, China
Background/Purpose: Ankylosing spondylitis (AS) is an inflammatory disease of the spinal joints leading to progressive loss of spinal mobility and chronic pain. Gutdysbiosis has been…
Abstract Number: 2546 • ACR Convergence 2023
Anti-infliximab Antibodies as a Marker of Drug Survival and Tapering in Ankylosing Spondylitis Patients: 12 Years Follow-up
CLARISSA PIMENTEL, ANA CRISTINA MEDEIROS-RIBEIRO, ANDREA SHIMABUCO, PERCIVAL SAMPAIO-BARROS, JULIO CESAR MORAES, CLAUDIA SCHAINBERG, CELIO GONÇALVES, ELAINE LEON, LEONARD KUPPA, Sandra Pasoto, NADIA AIKAWA, CLOVIS SILVA, Eloisa Bonfa and CARLA SAAD, University of São Paulo, São Paulo, Brazil
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) therapies were one of the major advances in the treatment of Ankylosing Spondylitis (AS) patients. For infliximab, anti-drug antibodies…
Abstract Number: 0510 • ACR Convergence 2023
Bimekizumab Treatment Improved Key Patient-Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain, Fatigue, and Morning Stiffness: 52-Week Results from Two Phase 3 Studies
Philip J. Mease¹, Maxime Dougados², Maureen Dubreuil³, Marina Nighat Magrey⁴, Helena Marzo-Ortega⁵, Martin Rudwaleit⁶, Christine de la Loge⁷, Carmen Fleurinck⁸, Ute Massow⁹, Vanessa Taieb¹⁰ and Atul Deodhar¹¹, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ²Department of Rheumatology, Hôpital Cochin, University of Paris Cité, Paris, France, ³Department of Rheumatology, Boston University School of Medicine, Milton, MA, ⁴Case Western Reserve University, University Hospitals, Cleveland, OH, ⁵NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁶University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ⁷UCB Pharma, Brussels, Belgium, ⁸UCB Pharma, Oosterzele, Belgium, ⁹UCB Pharma, Monheim am Rhein, Germany, ¹⁰UCB Pharma, Colombes, France, ¹¹Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. In the phase 3 studies BE MOBILE 1 and…
Abstract Number: 0541 • ACR Convergence 2023
Treat-to-Target Strategy Implementation in Spondyloarthritis Patients of Real-World Clinical Practice: A Cross-Sectional Single-Center Study
Irini Flouri¹, Nestor Avgoustidis², Anastasios Eskitzis², Argyro Repa², Katerina Pateromichelaki², Sofia Pitsigavdaki³, Myrto Nikoloudaki², Maria Terizaki², George Bertsias⁴ and Prodromos Sidiropoulos⁴, ¹University of Crete Medical School, Heraklion, Greece, ²Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Heraklion, Greece, ³Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Crete, Greece, ⁴Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Greece; Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology Hellas (FORTH), Heraklion, Greece
Background/Purpose: Data regarding the adoption of the treat-to-target (T2T) approach aiming at inactive disease (ID), or low disease activity (LDA) in axial (axSpA) and peripheral…
Abstract Number: 1397 • ACR Convergence 2023
Sustainability of Clinical Response at Week 52 to Upadacitinib Among Patients with Axial SpA: Data from the SELECT-AXIS 1 and SELECT-AXIS 2 Trials
Victoria Navarro-Compán¹, Lianne Gensler², Martin Rudwaleit³, Fabiana Ganz⁴, Shirley Chen⁴, Jayne Stigler⁴, Anna Schmagel⁴ and Xenofon Baraliakos⁵, ¹Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ²University of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, CA, ³University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ⁴AbbVie, Inc., North Chicago, IL, ⁵Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Bochum, Germany
Background/Purpose: Upadacitinib 15 mg (UPA), an oral Janus kinase inhibitor, has shown efficacy and tolerability through 14 weeks in patients (pts) with active radiographic axial…

« Previous Page
1
…
6
7
8
9
10
…
62
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.